Bacteriophages targeting protective commensals impair resistance against Salmonella Typhimurium infection in gnotobiotic mice

PLoS Pathog. 2023 Aug 21;19(8):e1011600. doi: 10.1371/journal.ppat.1011600. eCollection 2023 Aug.

Abstract

Gut microbial communities protect the host against a variety of major human gastrointestinal pathogens. Bacteriophages (phages) are ubiquitous in nature and frequently ingested via food and drinking water. Moreover, they are an attractive tool for microbiome engineering due to the lack of known serious adverse effects on the host. However, the functional role of phages within the gastrointestinal microbiome remain poorly understood. Here, we investigated the effects of microbiota-directed phages on infection with the human enteric pathogen Salmonella enterica serovar Typhimurium (S. Tm), using a gnotobiotic mouse model (OMM14) for colonization resistance (CR). We show, that phage cocktails targeting Escherichia coli and Enterococcus faecalis acted in a strain-specific manner. They transiently reduced the population density of their respective target before establishing coexistence for up to 9 days. Infection susceptibility to S. Tm was markedly increased at an early time point after challenge with both phage cocktails. Surprisingly, OMM14 mice were also susceptible 7 days after a single phage inoculation, when the targeted bacterial populations were back to pre-phage administration density. Concluding, our work shows that phages that dynamically modulate the density of protective members of the gut microbiota can provide opportunities for invasion of bacterial pathogens, in particular at early time points after phage application. This suggests, that phages targeting protective members of the microbiota may increase the risk for Salmonella infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacteriophages*
  • Escherichia coli
  • Gastrointestinal Microbiome*
  • Humans
  • Mice
  • Microbiota*
  • Salmonella Infections*
  • Salmonella typhimurium

Grants and funding

This research was supported by Collaborative Research Center 1371 funded by the German Research Foundation (project number 395357507, sub-project P14 to B.S. and T.C.), the European Research Council (EVOGUTHEALTH; grant no. 865615 to B.S.), DFG-ANR project PhaStGut (STE 1971/11-1 to B.S., PRCI ANR-20-CE92-0048 to L.D.), the DFG Priority Programme SPP2330 (to B.S.), the German Center for Infection Research (DZIF) (TTU 06.712 to B. S. and TTU 06.709 to B. S.) and the Center for Gastrointestinal Microbiome Research (CEGIMIR to B. S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A.v.S., A.S.W. and E.W. received salary from the Collaborative Research Center CRC1371 funded by the German Research Foundation (project number 395357507, P08 and P14). M.S.S. received salary from the European Research Council (EVOGUTHEALTH; grant no. 865615).